<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01432730</url>
  </required_header>
  <id_info>
    <org_study_id>7264-006</org_study_id>
    <secondary_id>AF219-006</secondary_id>
    <secondary_id>MK-7264-006</secondary_id>
    <nct_id>NCT01432730</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006)</brief_title>
  <acronym>EPICC</acronym>
  <official_title>A Study to Assess the Efficacy of AF-219, a P2X3 Receptor Antagonist, in Subjects With Chronic Cough</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afferent Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Afferent Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind, placebo-controlled, crossover, single centre study of
      gefapixant (AF-219/MK-7264) in subjects with idiopathic chronic cough designed to evaluate
      the effectiveness of gefapixant in reducing daytime objective cough frequency. The primary
      objective of this study was to evaluate the effectiveness of gefapixant in reducing daytime
      objective cough frequency.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 22, 2011</start_date>
  <completion_date type="Actual">February 21, 2013</completion_date>
  <primary_completion_date type="Actual">February 7, 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in daytime objective cough frequency after 2 weeks gefapixant therapy compared with placebo treatment.</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Chronic Cough</condition>
  <arm_group>
    <arm_group_label>Gefapixant 300 mg&gt;Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gefapixant, 300 mg, twice daily (BID), oral for 2 weeks followed by a 2-week washout period and then placebo to gefapixant, BID, oral for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo&gt;Gefapixant 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo to gefapixant BID, oral for 2 weeks followed by a 2-week washout period and then gefapixant, 300 mg, BID, oral for 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefapixant</intervention_name>
    <description>Oral tablets, BID</description>
    <arm_group_label>Gefapixant 300 mg&gt;Placebo</arm_group_label>
    <arm_group_label>Placebo&gt;Gefapixant 300 mg</arm_group_label>
    <other_name>AF-219</other_name>
    <other_name>MK-7264</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablets, BID</description>
    <arm_group_label>Gefapixant 300 mg&gt;Placebo</arm_group_label>
    <arm_group_label>Placebo&gt;Gefapixant 300 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of cough for more than 8 weeks

          -  Normal chest radiograph

          -  Idiopathic or treatment resistant cough (idiopathic defined as a cough for which no
             objective evidence of an underlying trigger can be determined after investigation or a
             cough that is unresponsive to 8 weeks of targeted treatment for identified underlying
             triggers including reflux disease, asthma and post-nasal drip [treatment-resistant]).

        Exclusion Criteria:

          -  Current smoker

          -  Individuals who have given up smoking within the past 6 months, or those with &gt;20
             pack-year smoking history

          -  Treatment with an angiotensin-converting-enzyme inhibitor (ACE-inhibitor) as the
             potential cause of a subject's cough, or requiring treatment with an ACE-inhibitor
             during the study or within 4 weeks prior to Day 0

          -  Forced Expiratory Volume (FEV1)/Forced Vital Capacity (FVC) &lt;60%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaclyn A Smith, MB, ChB, MRCP, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of South Manchester</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>September 9, 2011</study_first_submitted>
  <study_first_submitted_qc>September 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2011</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cough</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

